Register Login
Register to leave comments
  • News bot May 4, 2026, 12:48 p.m.

    📋 ADC THERAPEUTICS SA (ADCT) - Financial Results

    Filing Date: 2026-05-04

    Accepted: 2026-05-04 07:43:27

    Event Type: Financial Results

    Event Details:

    ADC THERAPEUTICS SA (ADCT) Reports the reporting period Financial Results ADC THERAPEUTICS SA (ADCT) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: (3,615)
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 231008
      • anticipated by year endFirst quarter 2026
      • anticipated in 2Q 2026
      • anticipated in the second quarter, full results expected from both LOTIS-5 and LOTIS-7 by year-end, as well as additional updates from the investigator-initiated studies in indolent lymphomas ahead. We believe that we are well-positioned to expand ZYNLONTA’s role across B-cell malignancies, accelerating our expected growth trajectory starting in 2027

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Loss From Operations -25.25K -28.46K $3.22K +11.31%
    Other Income Expense Interest Income 1.99K 2.05K $-60.00 -2.92%
    Other Income Expense Interest Expense -12.35K -12.23K $-119.00 -0.97%
    Other Income Expense Net Loss -32.97K -32.97K $0.00 +0.00%
    Net Loss Per Share Net Loss Per Share -0.21 -0.21 $0.00 +0.00%
    Operating Lease Right Of Use Assets 1.20K 1.30K $-97.00 -7.48%
    Current Liabilities Accounts Payable 5.29K 5.29K $0.00 +0.00%
    Other Long Term Liabilities 5.00K 2.81K $2.19K +77.86%
    Net Loss -32.97K -32.97K $0.00 +0.00%
    Net Loss Per Share -0.13 -0.13 $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ADC THERAPEUTICS SA
    • Ticker Symbol: ADCT

Search

News categories